In the AFP-negative group, 76.9% (30/39) of HCC patients had elevated circulating miR-19-3p levels (≥1.9), while in the AFP-positive group, high expression of miR-19-3p was found in 71.0% (22/31) of patients. This evidence concerns the gene AFP and hepatocellular carcinoma.